JP2007517543A - ポリマー化合物とその使用法 - Google Patents

ポリマー化合物とその使用法 Download PDF

Info

Publication number: JP2007517543A
Authority: JP; Japan
Prior art keywords: inhibitor; fiber formation; polymer; reactant; formation inhibitor
Prior art date: 2003-11-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2006541670A

Other languages

English (en)

Japanese (ja)

Other versions

JP2007517543A5 (no

Inventor

ウィリアムエル．ハンター，

デイビッドエム．グラベット，

フィリップエム．トレイキス，

アーピタマイティ，

リチャードティー．リギンズ，

アニコタカクス−コックス，

ルイアベラル，

トロイエー．イー．ロス，

ダーチグアン，

カイユエワン，

Original Assignee

アンジオテックインターナショナルアーゲー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-20

Filing date

2004-11-22

Publication date

2007-07-05

2004-11-10 Priority claimed from US10/986,231 external-priority patent/US20050181977A1/en

2004-11-22 Application filed by アンジオテックインターナショナルアーゲー filed Critical アンジオテックインターナショナルアーゲー

2007-07-05 Publication of JP2007517543A publication Critical patent/JP2007517543A/ja

2008-01-17 Publication of JP2007517543A5 publication Critical patent/JP2007517543A5/ja

Status Pending legal-status Critical Current

Links

229920000642 polymer Polymers 0.000 title claims abstract 499
150000001875 compounds Chemical class 0.000 title claims abstract 218
239000003112 inhibitor Substances 0.000 claims abstract 1084
230000015572 biosynthetic process Effects 0.000 claims abstract 729
239000000835 fiber Substances 0.000 claims abstract 701
206010016654 Fibrosis Diseases 0.000 claims abstract 287
230000004761 fibrosis Effects 0.000 claims abstract 287
239000000203 mixture Substances 0.000 claims abstract 57
239000007943 implant Substances 0.000 claims abstract 26
238000011282 treatment Methods 0.000 claims abstract 7
238000000034 method Methods 0.000 claims 1658
239000000376 reactant Substances 0.000 claims 451
108010035532 Collagen Proteins 0.000 claims 114
102000008186 Collagen Human genes 0.000 claims 114
229920001436 collagen Polymers 0.000 claims 114
229960005475 antiinfective agent Drugs 0.000 claims 94
239000004599 antimicrobial Substances 0.000 claims 94
210000001519 tissue Anatomy 0.000 claims 49
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 48
239000005557 antagonist Substances 0.000 claims 48
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 48
102000004169 proteins and genes Human genes 0.000 claims 47
108090000623 proteins and genes Proteins 0.000 claims 47
125000003277 amino group Chemical group 0.000 claims 36
229940045799 anthracyclines and related substance Drugs 0.000 claims 36
125000003396 thiol group Chemical group [H]S* 0.000 claims 36
230000002924 anti-infective effect Effects 0.000 claims 32
229920000233 poly(alkylene oxides) Polymers 0.000 claims 30
229920001281 polyalkylene Polymers 0.000 claims 30
239000000556 agonist Substances 0.000 claims 29
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 24
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 24
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 24
108010039918 Polylysine Proteins 0.000 claims 24
229940121375 antifungal agent Drugs 0.000 claims 24
239000003429 antifungal agent Substances 0.000 claims 24
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 24
229940043355 kinase inhibitor Drugs 0.000 claims 24
235000014655 lactic acid Nutrition 0.000 claims 24
239000004310 lactic acid Substances 0.000 claims 24
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 24
229960001237 podophyllotoxin Drugs 0.000 claims 24
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical group COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 24
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 24
229920000656 polylysine Polymers 0.000 claims 24
239000004037 angiogenesis inhibitor Substances 0.000 claims 19
229920001059 synthetic polymer Polymers 0.000 claims 19
FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical group N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 18
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 18
229940123034 Heat shock protein 90 antagonist Drugs 0.000 claims 18
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 18
229940122696 MAP kinase inhibitor Drugs 0.000 claims 18
230000006870 function Effects 0.000 claims 18
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 18
239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 18
230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 18
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 18
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 18
239000003757 phosphotransferase inhibitor Substances 0.000 claims 18
238000003786 synthesis reaction Methods 0.000 claims 18
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 18
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 18
239000003795 chemical substances by application Substances 0.000 claims 17
PGEGFAGJACEMIS-UHFFFAOYSA-N carbon dioxide;pyrrolidine-2,5-dione Chemical group O=C=O.O=C1CCC(=O)N1 PGEGFAGJACEMIS-UHFFFAOYSA-N 0.000 claims 16
230000008878 coupling Effects 0.000 claims 15
238000010168 coupling process Methods 0.000 claims 15
238000005859 coupling reaction Methods 0.000 claims 15
210000004204 blood vessel Anatomy 0.000 claims 14
230000003872 anastomosis Effects 0.000 claims 13
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 12
WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical group FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 claims 12
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 12
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 12
108010049003 Fibrinogen Proteins 0.000 claims 12
102000008946 Fibrinogen Human genes 0.000 claims 12
229940122331 Fibrinogen antagonist Drugs 0.000 claims 12
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 12
108010010803 Gelatin Proteins 0.000 claims 12
229940118547 Guanylate cyclase stimulant Drugs 0.000 claims 12
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 12
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical group NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 12
229940122255 Microtubule inhibitor Drugs 0.000 claims 12
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 12
229930012538 Paclitaxel Natural products 0.000 claims 12
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 12
229920000229 biodegradable polyester Polymers 0.000 claims 12
239000004622 biodegradable polyester Substances 0.000 claims 12
229920002988 biodegradable polymer Polymers 0.000 claims 12
239000004621 biodegradable polymer Substances 0.000 claims 12
229940127093 camptothecin Drugs 0.000 claims 12
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 12
GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims 12
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 12
229960004679 doxorubicin Drugs 0.000 claims 12
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 12
229960005420 etoposide Drugs 0.000 claims 12
229940012952 fibrinogen Drugs 0.000 claims 12
229960002949 fluorouracil Drugs 0.000 claims 12
239000004052 folic acid antagonist Substances 0.000 claims 12
229920000159 gelatin Polymers 0.000 claims 12
239000008273 gelatin Substances 0.000 claims 12
235000019322 gelatine Nutrition 0.000 claims 12
235000011852 gelatine desserts Nutrition 0.000 claims 12
229960001330 hydroxycarbamide Drugs 0.000 claims 12
231100000782 microtubule inhibitor Toxicity 0.000 claims 12
229960001156 mitoxantrone Drugs 0.000 claims 12
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical group O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 12
229960001592 paclitaxel Drugs 0.000 claims 12
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims 12
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 12
229920001223 polyethylene glycol Polymers 0.000 claims 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 12
229960002930 sirolimus Drugs 0.000 claims 12
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 12
229960001967 tacrolimus Drugs 0.000 claims 12
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 12
150000003573 thiols Chemical class 0.000 claims 12
239000003614 peroxisome proliferator Substances 0.000 claims 10
102000005962 receptors Human genes 0.000 claims 10
108020003175 receptors Proteins 0.000 claims 10
108020004414 DNA Proteins 0.000 claims 8
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical group O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 7
229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 7
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 7
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 7
239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 7
230000033115 angiogenesis Effects 0.000 claims 7
229940121369 angiogenesis inhibitor Drugs 0.000 claims 7
210000004027 cell Anatomy 0.000 claims 7
210000002744 extracellular matrix Anatomy 0.000 claims 7
210000002950 fibroblast Anatomy 0.000 claims 7
230000019305 fibroblast migration Effects 0.000 claims 7
230000035755 proliferation Effects 0.000 claims 7
230000008929 regeneration Effects 0.000 claims 7
238000011069 regeneration method Methods 0.000 claims 7
230000007838 tissue remodeling Effects 0.000 claims 7
DOEWDSDBFRHVAP-KRXBUXKQSA-N (E)-3-tosylacrylonitrile Chemical group CC1=CC=C(S(=O)(=O)\C=C\C#N)C=C1 DOEWDSDBFRHVAP-KRXBUXKQSA-N 0.000 claims 6
101710175516 14 kDa zinc-binding protein Proteins 0.000 claims 6
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 6
YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 6
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims 6
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 6
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 6
239000005541 ACE inhibitor Substances 0.000 claims 6
102000055025 Adenosine deaminases Human genes 0.000 claims 6
108010088751 Albumins Proteins 0.000 claims 6
102000009027 Albumins Human genes 0.000 claims 6
229940122195 Alpha2 integrin antagonist Drugs 0.000 claims 6
229940086440 Angiotensin I converting enzyme inhibitor Drugs 0.000 claims 6
229940123413 Angiotensin II antagonist Drugs 0.000 claims 6
102000000412 Annexin Human genes 0.000 claims 6
108050008874 Annexin Proteins 0.000 claims 6
108010039627 Aprotinin Proteins 0.000 claims 6
229940122361 Bisphosphonate Drugs 0.000 claims 6
102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 6
229940123003 Cathepsin inhibitor Drugs 0.000 claims 6
229940123587 Cell cycle inhibitor Drugs 0.000 claims 6
229940122444 Chemokine receptor antagonist Drugs 0.000 claims 6
108020005124 DNA Adducts Proteins 0.000 claims 6
102000003915 DNA Topoisomerases Human genes 0.000 claims 6
108090000323 DNA Topoisomerases Proteins 0.000 claims 6
229940126161 DNA alkylating agent Drugs 0.000 claims 6
239000012624 DNA alkylating agent Substances 0.000 claims 6
230000006820 DNA synthesis Effects 0.000 claims 6
229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 6
229940122858 Elastase inhibitor Drugs 0.000 claims 6
229940118365 Endothelin receptor antagonist Drugs 0.000 claims 6
229940122586 Enkephalinase inhibitor Drugs 0.000 claims 6
102400001368 Epidermal growth factor Human genes 0.000 claims 6
101800003838 Epidermal growth factor Proteins 0.000 claims 6
102100029951 Estrogen receptor beta Human genes 0.000 claims 6
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 6
108010054218 Factor VIII Proteins 0.000 claims 6
102000001690 Factor VIII Human genes 0.000 claims 6
229940123583 Factor Xa inhibitor Drugs 0.000 claims 6
229940124226 Farnesyltransferase inhibitor Drugs 0.000 claims 6
108050007372 Fibroblast Growth Factor Proteins 0.000 claims 6
102000018233 Fibroblast Growth Factor Human genes 0.000 claims 6
JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 6
101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 6
229940122296 IKK2 inhibitor Drugs 0.000 claims 6
108010087227 IMP Dehydrogenase Proteins 0.000 claims 6
102000006674 IMP dehydrogenase Human genes 0.000 claims 6
229940122355 Insulin sensitizer Drugs 0.000 claims 6
102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
101710149643 Integrin alpha-IIb Proteins 0.000 claims 6
108010008212 Integrin alpha4beta1 Proteins 0.000 claims 6
108010002352 Interleukin-1 Proteins 0.000 claims 6
108090000978 Interleukin-4 Proteins 0.000 claims 6
229940123313 MCP-1 antagonist Drugs 0.000 claims 6
229940124761 MMP inhibitor Drugs 0.000 claims 6
102000029749 Microtubule Human genes 0.000 claims 6
108091022875 Microtubule Proteins 0.000 claims 6
229930192392 Mitomycin Natural products 0.000 claims 6
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 6
RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical group C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 claims 6
229940123134 Nitric oxide inhibitor Drugs 0.000 claims 6
229940121682 Osteoclast inhibitor Drugs 0.000 claims 6
108091008606 PDGF receptors Proteins 0.000 claims 6
229940126033 PPAR agonist Drugs 0.000 claims 6
229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 6
229940121927 Phospholipase A1 inhibitor Drugs 0.000 claims 6
102000015439 Phospholipases Human genes 0.000 claims 6
108010064785 Phospholipases Proteins 0.000 claims 6
102000013566 Plasminogen Human genes 0.000 claims 6
108010051456 Plasminogen Proteins 0.000 claims 6
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 6
229940120646 Platelet-derived growth factor receptor kinase inhibitor Drugs 0.000 claims 6
229940123924 Protein kinase C inhibitor Drugs 0.000 claims 6
229940123752 RNA synthesis inhibitor Drugs 0.000 claims 6
229940122756 Retinoic acid receptor antagonist Drugs 0.000 claims 6
108091028664 Ribonucleotide Proteins 0.000 claims 6
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 6
229940123237 Taxane Drugs 0.000 claims 6
108090000190 Thrombin Proteins 0.000 claims 6
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 6
229940122435 VCAM-1 antagonist Drugs 0.000 claims 6
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 6
108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 claims 6
229940122803 Vinca alkaloid Drugs 0.000 claims 6
108010031318 Vitronectin Proteins 0.000 claims 6
102100035140 Vitronectin Human genes 0.000 claims 6
LVBMFPUTQOHXQE-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate Chemical group NCCCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N LVBMFPUTQOHXQE-UHFFFAOYSA-N 0.000 claims 6
238000009825 accumulation Methods 0.000 claims 6
239000002253 acid Substances 0.000 claims 6
125000005227 alkyl sulfonate group Chemical group 0.000 claims 6
239000002333 angiotensin II receptor antagonist Substances 0.000 claims 6
239000003242 anti bacterial agent Substances 0.000 claims 6
229940121363 anti-inflammatory agent Drugs 0.000 claims 6
239000002260 anti-inflammatory agent Substances 0.000 claims 6
230000000340 anti-metabolite Effects 0.000 claims 6
239000003146 anticoagulant agent Substances 0.000 claims 6
229940100197 antimetabolite Drugs 0.000 claims 6
239000002256 antimetabolite Substances 0.000 claims 6
229960004676 antithrombotic agent Drugs 0.000 claims 6
230000006907 apoptotic process Effects 0.000 claims 6
229960004405 aprotinin Drugs 0.000 claims 6
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical group CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 6
229960005207 auranofin Drugs 0.000 claims 6
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 6
229940092705 beclomethasone Drugs 0.000 claims 6
230000003115 biocidal effect Effects 0.000 claims 6
150000004663 bisphosphonates Chemical group 0.000 claims 6
239000011612 calcitriol Substances 0.000 claims 6
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 6
159000000007 calcium salts Chemical class 0.000 claims 6
150000001720 carbohydrates Chemical class 0.000 claims 6
235000014633 carbohydrates Nutrition 0.000 claims 6
239000002559 chemokine receptor antagonist Substances 0.000 claims 6
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
229960004316 cisplatin Drugs 0.000 claims 6
239000003086 colorant Substances 0.000 claims 6
239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 6
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 6
230000001086 cytosolic effect Effects 0.000 claims 6
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 6
229960003957 dexamethasone Drugs 0.000 claims 6
UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical group OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 claims 6
239000003534 dna topoisomerase inhibitor Substances 0.000 claims 6
239000003602 elastase inhibitor Substances 0.000 claims 6
239000002308 endothelin receptor antagonist Substances 0.000 claims 6
239000002792 enkephalinase inhibitor Substances 0.000 claims 6
229940116977 epidermal growth factor Drugs 0.000 claims 6
102000015694 estrogen receptors Human genes 0.000 claims 6
108010038795 estrogen receptors Proteins 0.000 claims 6
229960005167 everolimus Drugs 0.000 claims 6
229960000301 factor viii Drugs 0.000 claims 6
229940126864 fibroblast growth factor Drugs 0.000 claims 6
QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 6
239000003862 glucocorticoid Substances 0.000 claims 6
229960002706 gusperimus Drugs 0.000 claims 6
IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical group NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 claims 6
229960001340 histamine Drugs 0.000 claims 6
239000003485 histamine H2 receptor antagonist Substances 0.000 claims 6
239000003395 histamine H3 receptor antagonist Substances 0.000 claims 6
229920002674 hyaluronan Polymers 0.000 claims 6
229960003160 hyaluronic acid Drugs 0.000 claims 6
230000007062 hydrolysis Effects 0.000 claims 6
238000006460 hydrolysis reaction Methods 0.000 claims 6
230000000774 hypoallergenic effect Effects 0.000 claims 6
239000002955 immunomodulating agent Substances 0.000 claims 6
229940121354 immunomodulator Drugs 0.000 claims 6
230000002584 immunomodulator Effects 0.000 claims 6
229960003444 immunosuppressant agent Drugs 0.000 claims 6
230000001861 immunosuppressant effect Effects 0.000 claims 6
239000003018 immunosuppressive agent Substances 0.000 claims 6
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 6
239000012948 isocyanate Substances 0.000 claims 6
150000002513 isocyanates Chemical class 0.000 claims 6
239000003199 leukotriene receptor blocking agent Substances 0.000 claims 6
239000003120 macrolide antibiotic agent Substances 0.000 claims 6
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 6
229960004961 mechlorethamine Drugs 0.000 claims 6
229960000485 methotrexate Drugs 0.000 claims 6
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 6
210000004688 microtubule Anatomy 0.000 claims 6
229960004857 mitomycin Drugs 0.000 claims 6
229960000951 mycophenolic acid Drugs 0.000 claims 6
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 6
239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims 6
239000002740 neurokinin 3 receptor antagonist Substances 0.000 claims 6
229960003966 nicotinamide Drugs 0.000 claims 6
235000005152 nicotinamide Nutrition 0.000 claims 6
239000011570 nicotinamide Substances 0.000 claims 6
OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical group NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 6
230000000269 nucleophilic effect Effects 0.000 claims 6
239000002773 nucleotide Substances 0.000 claims 6
125000003729 nucleotide group Chemical group 0.000 claims 6
239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 6
239000002571 phosphodiesterase inhibitor Substances 0.000 claims 6
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical group C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 6
229960005330 pimecrolimus Drugs 0.000 claims 6
229910052697 platinum Inorganic materials 0.000 claims 6
150000003058 platinum compounds Chemical group 0.000 claims 6
239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 6
239000003881 protein kinase C inhibitor Substances 0.000 claims 6
239000003909 protein kinase inhibitor Substances 0.000 claims 6
238000001243 protein synthesis Methods 0.000 claims 6
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 6
230000006824 pyrimidine synthesis Effects 0.000 claims 6
125000000714 pyrimidinyl group Chemical group 0.000 claims 6
229940044551 receptor antagonist Drugs 0.000 claims 6
239000002464 receptor antagonist Substances 0.000 claims 6
102000000568 rho-Associated Kinases Human genes 0.000 claims 6
108010041788 rho-Associated Kinases Proteins 0.000 claims 6
239000002336 ribonucleotide Substances 0.000 claims 6
125000002652 ribonucleotide group Chemical group 0.000 claims 6
239000011435 rock Substances 0.000 claims 6
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 6
229960002855 simvastatin Drugs 0.000 claims 6
150000003431 steroids Chemical class 0.000 claims 6
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 6
229960004072 thrombin Drugs 0.000 claims 6
239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 6
229940044693 topoisomerase inhibitor Drugs 0.000 claims 6
230000014616 translation Effects 0.000 claims 6
229950007229 tresperimus Drugs 0.000 claims 6
239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 6
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 6
239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 6
229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 6
239000005483 tyrosine kinase inhibitor Substances 0.000 claims 6
150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 6
YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical group C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 6
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 6
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical group N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 6
229950009819 zotarolimus Drugs 0.000 claims 6
230000005778 DNA damage Effects 0.000 claims 5
231100000277 DNA damage Toxicity 0.000 claims 5
102000006795 dihydrofolate reductase activity proteins Human genes 0.000 claims 5
108040000939 dihydrofolate reductase activity proteins Proteins 0.000 claims 5
229910052751 metal Inorganic materials 0.000 claims 5
239000002184 metal Substances 0.000 claims 5
230000002792 vascular Effects 0.000 claims 5
108010047303 von Willebrand Factor Proteins 0.000 claims 5
102100036537 von Willebrand factor Human genes 0.000 claims 5
229960001134 von willebrand factor Drugs 0.000 claims 5
230000002112 DNA intercalation Effects 0.000 claims 4
239000002473 artificial blood Substances 0.000 claims 4
239000000463 material Substances 0.000 claims 4
102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
210000000613 ear canal Anatomy 0.000 claims 3
230000002496 gastric effect Effects 0.000 claims 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 3
238000009423 ventilation Methods 0.000 claims 3
210000001367 artery Anatomy 0.000 claims 2
239000008280 blood Substances 0.000 claims 2
210000004369 blood Anatomy 0.000 claims 2
210000004351 coronary vessel Anatomy 0.000 claims 2
210000002216 heart Anatomy 0.000 claims 2
210000003462 vein Anatomy 0.000 claims 2
239000012625 DNA intercalator Substances 0.000 claims 1
208000010412 Glaucoma Diseases 0.000 claims 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
230000003881 arterial anastomosis Effects 0.000 claims 1
239000000560 biocompatible material Substances 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
210000003169 central nervous system Anatomy 0.000 claims 1
230000000112 colonic effect Effects 0.000 claims 1
238000004891 communication Methods 0.000 claims 1
238000013461 design Methods 0.000 claims 1
238000000502 dialysis Methods 0.000 claims 1
OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
210000000959 ear middle Anatomy 0.000 claims 1
239000013536 elastomeric material Substances 0.000 claims 1
210000002388 eustachian tube Anatomy 0.000 claims 1
239000012530 fluid Substances 0.000 claims 1
210000000232 gallbladder Anatomy 0.000 claims 1
210000003709 heart valve Anatomy 0.000 claims 1
238000003780 insertion Methods 0.000 claims 1
230000037431 insertion Effects 0.000 claims 1
230000007246 mechanism Effects 0.000 claims 1
229910001092 metal group alloy Inorganic materials 0.000 claims 1
238000012544 monitoring process Methods 0.000 claims 1
210000003101 oviduct Anatomy 0.000 claims 1
210000002307 prostate Anatomy 0.000 claims 1
230000009467 reduction Effects 0.000 claims 1
210000004872 soft tissue Anatomy 0.000 claims 1
210000001631 vena cava inferior Anatomy 0.000 claims 1
230000003878 venous anastomosis Effects 0.000 claims 1
208000032544 Cicatrix Diseases 0.000 abstract 1
208000002260 Keloid Diseases 0.000 abstract 1
208000031737 Tissue Adhesions Diseases 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
210000000845 cartilage Anatomy 0.000 abstract 1
238000011065 in-situ storage Methods 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
210000001117 keloid Anatomy 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
231100000241 scar Toxicity 0.000 abstract 1
230000037387 scars Effects 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Surgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)
Prostheses (AREA)
External Artificial Organs (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

JP2006541670A 2003-11-20 2004-11-22 ポリマー化合物とその使用法 Pending JP2007517543A (ja)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US52390803P	2003-11-20	2003-11-20
US52522603P	2003-11-24	2003-11-24
US52654103P	2003-12-03	2003-12-03
US56656904P	2004-04-28	2004-04-28
US58686104P	2004-07-09	2004-07-09
US61107704P	2004-09-17	2004-09-17
US10/986,231 US20050181977A1 (en)	2003-11-10	2004-11-10	Medical implants and anti-scarring agents
PCT/US2004/039389 WO2005051452A2 (en)	2003-11-20	2004-11-22	Polymer compositions and methods for their use

Publications (2)

Publication Number	Publication Date
JP2007517543A true JP2007517543A (ja)	2007-07-05
JP2007517543A5 JP2007517543A5 (no)	2008-01-17

Family

ID=34637499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2006541670A Pending JP2007517543A (ja)	2003-11-20	2004-11-22	ポリマー化合物とその使用法

Country Status (6)

Country	Link
EP (1)	EP1684819A2 (no)
JP (1)	JP2007517543A (no)
AU (1)	AU2004293071A1 (no)
CA (1)	CA2536181A1 (no)
IL (1)	IL174641A0 (no)
WO (2)	WO2005051316A2 (no)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007135965A (ja) *	2005-11-21	2007-06-07	Tohoku Univ	体内留置多機能ステントおよびその製造方法
JP2011528275A (ja) *	2008-07-17	2011-11-17	ミセルテクノロジーズ，インク．	薬物送達医療デバイス
JP2012500087A (ja) *	2008-08-19	2012-01-05	ウォーソー・オーソペディック・インコーポレーテッド	着色剤を含む骨形成組成物
JP2013063322A (ja) *	2006-11-06	2013-04-11	Tyrx Inc	埋込型医療機器のための吸収性パウチ
US9023114B2 (en)	2006-11-06	2015-05-05	Tyrx, Inc.	Resorbable pouches for implantable medical devices
JP2016518485A (ja) *	2013-04-10	2016-06-23	ザユニヴァーシティーオブメルボルン	再生医学用及び組織工学用生分解性ネットワークポリマー
KR20200010567A (ko) *	2011-10-28	2020-01-30	백스터 인터내셔널 인코포레이티드	뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법
JP7691565B1 (ja) *	2024-06-10	2025-06-11	真由美大石	生体組織の瘢痕化を抑制するための創傷用足場材

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1539157E (pt)	2002-09-18	2013-10-04	Univ Pennsylvania	Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
CN1882338A (zh)	2003-09-18	2006-12-20	马库赛特公司	经巩膜递送
WO2005049105A2 (en) *	2003-11-10	2005-06-02	Angiotech International Ag	Medical implants and anti-scarring agents
US8663639B2 (en)	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
WO2006086744A1 (en)	2005-02-09	2006-08-17	Macusight, Inc.	Formulations for ocular treatment
US20100040666A1 (en) *	2005-06-24	2010-02-18	Hiroshi Azuma	Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
JP5528708B2 (ja)	2006-02-09	2014-06-25	参天製薬株式会社	安定な製剤ならびにそれらを調製および使用する方法
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
WO2008011615A2 (en)	2006-07-20	2008-01-24	Orbusneich Medical, Inc.	Bioabsorbable polymeric composition for a medical device
US7959942B2 (en)	2006-10-20	2011-06-14	Orbusneich Medical, Inc.	Bioabsorbable medical device with coating
EP2073754A4 (en)	2006-10-20	2012-09-26	Orbusneich Medical Inc	BIOABSORBABLE POLYMER COMPOSITION AND MEDICAL DEVICE BACKGROUND
US7801624B1 (en)	2007-01-16	2010-09-21	Pacesetter, Inc.	Reduced perforation distal tip for an implantable cardiac electrotherapy lead
US9305334B2 (en)	2007-03-08	2016-04-05	Sync-Rx, Ltd.	Luminal background cleaning
US9968256B2 (en)	2007-03-08	2018-05-15	Sync-Rx Ltd.	Automatic identification of a tool
US11197651B2 (en)	2007-03-08	2021-12-14	Sync-Rx, Ltd.	Identification and presentation of device-to-vessel relative motion
US10716528B2 (en)	2007-03-08	2020-07-21	Sync-Rx, Ltd.	Automatic display of previously-acquired endoluminal images
US8700130B2 (en)	2007-03-08	2014-04-15	Sync-Rx, Ltd.	Stepwise advancement of a medical tool
US11064964B2 (en)	2007-03-08	2021-07-20	Sync-Rx, Ltd	Determining a characteristic of a lumen by measuring velocity of a contrast agent
US9629571B2 (en)	2007-03-08	2017-04-25	Sync-Rx, Ltd.	Co-use of endoluminal data and extraluminal imaging
EP2358269B1 (en)	2007-03-08	2019-04-10	Sync-RX, Ltd.	Image processing and tool actuation for medical procedures
WO2008107905A2 (en)	2007-03-08	2008-09-12	Sync-Rx, Ltd.	Imaging and tools for use with moving organs
US9375164B2 (en)	2007-03-08	2016-06-28	Sync-Rx, Ltd.	Co-use of endoluminal data and extraluminal imaging
US8455459B2 (en)	2007-08-02	2013-06-04	Medicis Pharmaceutical Corporation	Method of applying an injectable filler
US9974509B2 (en)	2008-11-18	2018-05-22	Sync-Rx Ltd.	Image super enhancement
US11064903B2 (en)	2008-11-18	2021-07-20	Sync-Rx, Ltd	Apparatus and methods for mapping a sequence of images to a roadmap image
US8855744B2 (en)	2008-11-18	2014-10-07	Sync-Rx, Ltd.	Displaying a device within an endoluminal image stack
US10362962B2 (en)	2008-11-18	2019-07-30	Synx-Rx, Ltd.	Accounting for skipped imaging locations during movement of an endoluminal imaging probe
US9101286B2 (en)	2008-11-18	2015-08-11	Sync-Rx, Ltd.	Apparatus and methods for determining a dimension of a portion of a stack of endoluminal data points
US9144394B2 (en)	2008-11-18	2015-09-29	Sync-Rx, Ltd.	Apparatus and methods for determining a plurality of local calibration factors for an image
US9095313B2 (en)	2008-11-18	2015-08-04	Sync-Rx, Ltd.	Accounting for non-uniform longitudinal motion during movement of an endoluminal imaging probe
HUP1000385A2 (en)	2010-07-21	2012-01-30	Medicontur Orvostechnikai Kft	Alkane diol derivatives preparation thereof and based on them
EP2625264B1 (en)	2010-10-08	2022-12-07	Terumo BCT, Inc.	Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US9492383B2 (en)	2011-04-20	2016-11-15	Carbylan Therapeutics, Inc.	Rapid in-situ gel forming compositions prepared via reaction of vinyl sulfone derivatized hyaluronic acid with thiol derivatized polyethylene glycol at alkaline pH
US10307292B2 (en)	2011-07-18	2019-06-04	Mor Research Applications Ltd	Device for adjusting the intraocular pressure
JP6134789B2 (ja)	2012-06-26	2017-05-24	シンク−アールエックス，リミティド	管腔器官における流れに関連する画像処理
EP3068866B1 (en)	2013-11-16	2018-04-25	Terumo BCT, Inc.	Expanding cells in a bioreactor
JP6783143B2 (ja)	2014-03-25	2020-11-11	テルモビーシーティー、インコーポレーテッド	培地の受動的補充
CN106715676A (zh)	2014-09-26	2017-05-24	泰尔茂比司特公司	按计划供养
WO2017004592A1 (en)	2015-07-02	2017-01-05	Terumo Bct, Inc.	Cell growth with mechanical stimuli
CN109415696A (zh)	2016-05-25	2019-03-01	泰尔茂比司特公司	细胞扩增
US11685883B2 (en)	2016-06-07	2023-06-27	Terumo Bct, Inc.	Methods and systems for coating a cell growth surface
US11104874B2 (en)	2016-06-07	2021-08-31	Terumo Bct, Inc.	Coating a bioreactor
US11096781B2 (en)	2016-08-01	2021-08-24	Edwards Lifesciences Corporation	Prosthetic heart valve
US12234441B2 (en)	2017-03-31	2025-02-25	Terumo Bct, Inc.	Cell expansion
US11624046B2 (en)	2017-03-31	2023-04-11	Terumo Bct, Inc.	Cell expansion
US11702634B2 (en)	2017-03-31	2023-07-18	Terumo Bct, Inc.	Expanding cells in a bioreactor
CN108498905B (zh) *	2018-04-03	2024-08-06	广州迈普再生医学科技股份有限公司	用于双联混合注射器的腔镜型喷头及腔镜型双联混合注射器
EP3706619B1 (en)	2017-11-09	2024-04-24	ConvaTec Technologies Inc.	Ostomy monitoring system
WO2020030486A1 (en) *	2018-08-09	2020-02-13	Gambro Lundia Ab	Method for detection of flow obstruction in an extracorporeal circuit, apparatus and computer program
USD893514S1 (en)	2018-11-08	2020-08-18	11 Health And Technologies Limited	Display screen or portion thereof with graphical user interface
US20200254103A1 (en) *	2019-02-11	2020-08-13	John Mee	Method for treating neurological conditions and improving human cognition
CN114081672B (zh)	2020-08-24	2025-08-12	爱德华兹生命科学公司	用于将假体心脏瓣膜的连合部与原生瓣膜的连合部对准的方法和系统
US12357494B2 (en)	2020-10-15	2025-07-15	Convatec Technologies Inc.	Ostomy systems and methods
US12043823B2 (en)	2021-03-23	2024-07-23	Terumo Bct, Inc.	Cell capture and expansion
CN113281317B (zh) *	2021-05-14	2022-04-29	北京指真生物科技有限公司	一种含有花菁类化合物的编码微球及其制备方法和应用
US12209689B2 (en)	2022-02-28	2025-01-28	Terumo Kabushiki Kaisha	Multiple-tube pinch valve assembly
USD1099116S1 (en)	2022-09-01	2025-10-21	Terumo Bct, Inc.	Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115382028A (zh) *	2022-09-19	2022-11-25	郑州大学第一附属医院	一种可降解吻合器材料及其制备方法和应用
WO2024159015A1 (en) *	2023-01-25	2024-08-02	North Carolina State University	Compositions and methods relating to inhalable therapeutic compositions
CN118903564B (zh) *	2024-09-02	2025-11-04	嘉兴睿清医疗科技有限公司	一种羟基磷灰石复合聚酯微球及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002087563A2 (en) *	2001-05-01	2002-11-07	Angiotech Pharmaceuticals Inc.	Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
JP2003520830A (ja) *	2000-01-25	2003-07-08	エドワーズライフサイエンシーズコーポレイション	再狭窄および吻合内膜過形成処置のための送達系
WO2003092741A1 (en) *	2002-05-03	2003-11-13	Avi Biopharma, Inc.	Delivery of microparticle-conjugated drugs for inhibition of stenosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050208095A1 (en) *	2003-11-20	2005-09-22	Angiotech International Ag	Polymer compositions and methods for their use

2004
- 2004-11-22 JP JP2006541670A patent/JP2007517543A/ja active Pending
- 2004-11-22 AU AU2004293071A patent/AU2004293071A1/en not_active Abandoned
- 2004-11-22 CA CA002536181A patent/CA2536181A1/en not_active Abandoned
- 2004-11-22 WO PCT/US2004/039491 patent/WO2005051316A2/en not_active Ceased
- 2004-11-22 WO PCT/US2004/039389 patent/WO2005051452A2/en not_active Ceased
- 2004-11-22 EP EP04816983A patent/EP1684819A2/en not_active Withdrawn
2006
- 2006-03-30 IL IL174641A patent/IL174641A0/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003520830A (ja) *	2000-01-25	2003-07-08	エドワーズライフサイエンシーズコーポレイション	再狭窄および吻合内膜過形成処置のための送達系
WO2002087563A2 (en) *	2001-05-01	2002-11-07	Angiotech Pharmaceuticals Inc.	Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
WO2003092741A1 (en) *	2002-05-03	2003-11-13	Avi Biopharma, Inc.	Delivery of microparticle-conjugated drugs for inhibition of stenosis

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007135965A (ja) *	2005-11-21	2007-06-07	Tohoku Univ	体内留置多機能ステントおよびその製造方法
JP2013063322A (ja) *	2006-11-06	2013-04-11	Tyrx Inc	埋込型医療機器のための吸収性パウチ
US9023114B2 (en)	2006-11-06	2015-05-05	Tyrx, Inc.	Resorbable pouches for implantable medical devices
JP2011528275A (ja) *	2008-07-17	2011-11-17	ミセルテクノロジーズ，インク．	薬物送達医療デバイス
JP2012500087A (ja) *	2008-08-19	2012-01-05	ウォーソー・オーソペディック・インコーポレーテッド	着色剤を含む骨形成組成物
KR20200010567A (ko) *	2011-10-28	2020-01-30	백스터 인터내셔널 인코포레이티드	뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법
KR102184970B1 (ko) *	2011-10-28	2020-12-03	백스터 인터내셔널 인코포레이티드	뼈 지혈용 비-수성 조성물, 그의 사용 방법 및 제조 방법
JP2016518485A (ja) *	2013-04-10	2016-06-23	ザユニヴァーシティーオブメルボルン	再生医学用及び組織工学用生分解性ネットワークポリマー
US10179834B2 (en)	2013-04-10	2019-01-15	The University Of Melbourne	Biodegradable network polymers for regenerative medicine and tissue engineering
JP7691565B1 (ja) *	2024-06-10	2025-06-11	真由美大石	生体組織の瘢痕化を抑制するための創傷用足場材
WO2025258414A1 (ja) *	2024-06-10	2025-12-18	真由美大石	生体組織の瘢痕化を抑制するための創傷用足場材

Also Published As

Publication number	Publication date
WO2005051316A2 (en)	2005-06-09
WO2005051452A2 (en)	2005-06-09
EP1684819A2 (en)	2006-08-02
WO2005051316A3 (en)	2010-01-28
IL174641A0 (en)	2006-08-20
AU2004293071A1 (en)	2005-06-09
CA2536181A1 (en)	2005-06-09

Legal Events

Date	Code	Title	Description
2007-11-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071121
2007-11-22	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071121
2011-02-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110225
2011-07-29	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110728

Publication	Publication Date	Title
US20050175703A1 (en)	2005-08-11	Polymer compositions and methods for their use
JP2007517543A (ja)	2007-07-05	ポリマー化合物とその使用法
CN101420991A (zh)	2009-04-29	聚合物组合物及其使用方法
US20050177225A1 (en)	2005-08-11	Medical implants and anti-scarring agents
KR100974733B1 (ko)	2010-08-06	가교된 생합성물질을 형성하기 위한 조성물 및 시스템, 및이와 관련된 제조 및 사용 방법
US20050175664A1 (en)	2005-08-11	Implantable sensors and implantable pumps and anti-scarring agents
CN101094613A (zh)	2007-12-26	医用植入物和抗瘢痕形成剂